Sangamo Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
REGNRegeneron Pharmaceuticals, Inc. -0.06%734.702.6%$779.09m
MRNAModerna, Inc. 3.08%124.710.0%$632.83m
AMGNAmgen, Inc. 0.20%230.911.4%$625.00m
BIIBBiogen, Inc. 0.75%266.281.8%$591.71m
GILDGilead Sciences, Inc. 2.95%64.161.0%$546.30m
VRTXVertex Pharmaceuticals, Inc. 0.48%298.851.9%$428.89m
ILMNIllumina, Inc. 6.29%199.033.2%$374.40m
SNSSSunesis Pharmaceuticals, Inc. 0.24%4.150.7%$290.10m
SAVACassava Sciences, Inc. 1.98%42.320.0%$200.98m
BNTXBioNTech SE 2.25%139.750.0%$117.86m
NVAXNovavax, Inc. 5.54%19.6375.6%$90.48m
BMRNBioMarin Pharmaceutical, Inc. 1.04%87.604.2%$86.09m
ADTXAditxt, Inc. 4.73%4.210.0%$84.57m
PRTAProthena Corp. Plc 0.49%62.1313.8%$84.42m
NRBONeuroBo Pharmaceuticals, Inc. 2.56%13.600.0%$82.32m

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.